Covidien’s New Clinical Data is a Statement of Intent for its Peripheral Arterial Disease Business

Covidien has released positive final results from its DURABILITY II study and promising preliminary data from its DEFINITIVE AR Peripheral Artery Disease (PAD) trial involving some of its technologies. The results are sure to fuel its ongoing push into the peripheral vascular therapy area.

Report Points to Potential Impact of BioMimics 3D™ Peripheral Vascular Stent

The UK’s National Institute for Health Research (NIHR) has issued a technical report pointing to the potential for Veryan Medical’s BioMimics 3D™ Stent. It focuses on the potential advantage of a spiral stent that mimics the shape of a native vessel, but being a government body rather ducks the issue of whether it’s any good, leaving us wondering what use this report really is.

New Marketing VP at InspireMD

Embolic protection stent developer, InspireMD Inc. has announced David Blossom as Vice President of Global Marketing and Strategy. Blossom will be responsible for a global strategic marketing plan that addresses the emerging coronary, carotid and multiple vascular opportunities before the Company.

First for Gore as FDA Approves Prosthesis for Endovascular Repair of Aortic Dissection

W. L. Gore & Associates has gained FDA approval for its Conformable GORE® TAG® Thoracic Endoprosthesis for endovascular repair of acute and chronic Type B dissections of the descending thoracic aorta. This durable endoprosthesis is the only device to receive FDA approval for this indication and is designed for multiple thoracic etiologies.

European Clot Management Device Market To Exceed $170 Million By 2022

According to global market intelligence company Millennium Research Group, the European market for clot management devices will see moderate growth through 2022. Although a number of segments are mature, fast-growing segments such as endovascular treatments for acute ischemic stroke and venous thromboembolism underpin the growth forecast.

Most read

Latest

^